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Abstract  
Activating transcription factor-5 (ATF5) is a stress-response transcription factor induced upon 
different cell stressors like fasting, amino-acid limitation, cadmium or arsenite. ATF5 is also induced, 
and promotes transcription of anti-apoptotic target genes like MCL1, during the unfolded protein 
response (UPR) triggered by endoplasmic reticulum stress. In the brain, high ATF5 levels are found 
in gliomas and also in neural progenitor cells, which need to decrease their ATF5 levels for 
differentiation into mature neurons or glia. This initially led to believe that ATF5 is not expressed in 
adult neurons. More recently, we reported basal neuronal ATF5 expression in adult mouse brain 
and its neuroprotective induction during UPR in a mouse model of status epilepticus. Here we aimed 
to explore whether ATF5 is also expressed by neurons in human brain both in basal conditions and 
in Huntington’s disease (HD), where UPR has been described to be partially impaired due to 
defective ATF6 processing. Apart from confirming that ATF5 is present in human adult neurons, here 
we report accumulation of ATF5 within the characteristic polyglutamine-containing neuronal 
nuclear inclusions in brains of HD patients and mice. This correlates with decreased levels of soluble 
ATF5 and of its antiapoptotic target MCL1. We then confirmed the deleterious effect of ATF5 
deficiency in a Caenorhabditis elegans model of polyglutamine-induced toxicity. Finally, ATF5 
overexpression attenuated polyglutamine-induced apoptosis in a cell model of HD. These results 
reflect that decreased ATF5 in HD—probably secondary to sequestration into inclusions—renders 
neurons more vulnerable to mutant huntingtin-induced apoptosis and that ATF5-increasing 
interventions might have therapeutic potential for HD. 
 
Keywords:  Huntington’s disease, ATF5, MCL1, ER stress, UPR, neuroprotection 
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Introduction 
Activating transcription factor-5 (ATF5) [31] is a basic valine/leucine zipper (bZIP) transcription 
factor that belongs to the ATF/cAMP response-element binding protein (CREB) family [45]. Also 
known as ATFx or ATF7 [15], ATF5 is a stress-response transcription factor [16] as it is induced by 
different cell stressors such as fasting [38], amino acid limitation [48], cadmium chloride or sodium 
arsenite [43]. In line with this, and similar to the related transcription factors ATF4 and ATF6 [17], 
ATF5 is induced as part of the unfolded protein response (UPR) to cope with the stress induced by 
the accumulation of unfolded proteins in the endoplasmic reticulum (ER stress) [19, 41, 47, 49]. Such 
ATF5 induction upon ER stress has been reported to be due to increased transcription [19, 37] 
and/or to selective translation upon eIF2α-phosphorylation [47, 49]. Essentially, ATF5 plays a pro-
survival role as it promotes transcription of antiapoptotic genes such as MCL1 [10, 19, 37]. 
Accordingly, ATF5 is necessary for survival of many different cell types such as lymphocytes [35] or 
cardiomyocytes [46]. ATF5 protein expression decreases in cells undergoing apoptosis following 
growth factor deprivation [35] while its levels are increased and promote apoptotic resistance in a 
variety of human malignancies, including glioblastoma, breast, pancreatic, lung, and colon cancers 
[20, 27]. 
In the brain, highest ATF5 levels are detected in gliomas [1, 27, 37]. In non-pathological brain, high 
levels are also important for proliferation of neural progenitor cells and a significant decrease in 
their ATF5 levels is required for their differentiation into mature neurons or glial cells [2, 3, 24]. This 
led to the notion of ATF5 not being expressed in adult neurons [14]. However, we have 
demonstrated that mouse adult neurons maintain a steady state level of ATF5 expression which 
increases upon UPR-triggering stimuli such as tunicamycin or the status epilepticus caused by intra-
amygdala injection of kainic acid [41]. This neuronal ATF5 induction is believed to be neuroprotective 
as ATF5 overexpression attenuates ER stress-induced apoptosis in neurons [41]. 
4 
 
Huntington’s disease (HD) is the most common genetically determined neurodegenerative disease 
and belongs to the group of neurological disorders caused by expanded CAG triplet repeats 
encoding self-aggregating poly-glutamine (polyQ) tracts in their respective proteins [33]. HD is 
characterized by marked atrophy in the caudate and putamen and to a lesser extent in the cortex 
and by the presence of polyQ-containing inclusions bodies (IBs). ER stress activation and/or 
impairment is a common feature of most neurodegenerative diseases including HD [18] and we and 
others have previously reported impaired UPR execution in HD due to diminished processing of ATF6 
[11, 30]. In view of the putative neuroprotective role of ATF5 upon ER stress induction and its 
constitutive expression in mouse adult neurons [41], we decided to explore the status of ATF5 in HD 
mouse models and human tissue. 
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Materials and Methods 
 
Human brain tissue samples 
Brain specimens used in this study from frontal cortex and striatum of HD patients and controls 
were provided by Institute of Neuropathology (HUB-ICO-IDIBELL) Brain Bank (Hospitalet de 
Llobregat, Spain), the Neurological Tissue Bank of the IDIBAPS Biobank (Barcelona, Spain), the Banco 
de Tejidos Fundación Cien (BT-CIEN, Madrid, Spain), and the Netherlands Brain Bank (Amsterdam, 
The Netherlands). Written informed consent for brain removal after death for diagnostic and 
research purposes was obtained from brain donors and/or next of kin. Procedures, information 
and consent forms have been approved by the Bioethics Subcommittee of Consejo Superior de 
Investigaciones Científicas (CSIC, Madrid, Spain). When available, the neuropathological 
examination of HD cases to assign HD grade from 0–1 to 4 following Vonsattel’s criteria, and the 
number of CAG repeats is shown in Supplementary Table 1. The postmortem interval in tissue 
processing is also indicated in Supplementary Table 1. 
 
Mice 
R6/1 transgenic mice for the human exon-1-HTT gene [23] in B6CBAF1 background were housed at 
the Centro de Biología Molecular “Severo Ochoa” animal facility. Mice were housed four per cage 
with food and water available ad libitum and maintained in a temperature-controlled environment 
on a 12/12 h light–dark cycle with light onset at 0800 hours. Animal housing and maintenance 
protocols followed the guidelines of Council of Europe Convention ETS123. Animal experiments 
were performed under protocols (PROEX293/15) approved by the Centro de Biología Molecular 
Severo Ochoa Institutional Animal Care and Utilization Committee (Comité de Ética de 
Experimentación Animal del CBM, CEEA-CBM), Madrid, Spain. 
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Caenorhabditis elegans 
The standard methods used for culturing and maintenance of C. elegans were as previously 
described [40]. The strains used in this work are: N2, wild type DR subclone of CB original (Tc1 
pattern I), LD1325, atf-5(tm4397) X [12], VZ531 = vzEx173 [Punc-54::Q40::yfp], VZ533 = vzEx175 
[Punc-54::Q40::yfp], VZ534 = atf-5(tm4397) X; vzEx173 [Punc-54::Q40::yfp] and VZ535 = atf-
5(tm4397) X; vzEx175 [Punc-54::Q40::yfp]. All experiments were performed at 20 °C unless 
otherwise noted. All VZ strains are 6× backcrossed and LD1325 is 7× backcrossed with N2 wild type. 
 
Cell culture and transfection 
Neuro-2a neuroblastoma cells were cultured in 10% FBS (GIBCO) supplemented DMEM at 37 °C in 
a 5% CO2 atmosphere. The day before transfection 3 × 105 cells per condition were placed in a six 
well plate (Falcon), with or without glass coverslips, and allowed to attach to the plate. N2a cells 
were transfected (Lipofectamine 2000, Thermo Fisher) with the following construct combinations: 
PolyQ16 and pcDNA3; PolyQ94 and pcDNA3; PolyQ94 and pcDNA3-MYC-mATF5; PolyQ94 and 
p3XFlag-CMV10-Flag-mMcl-1. PolyQ16, PolyQ94, pcDNA3-MYC-mATF5 and p3XFlag-CMV10-Flag-
mMcl-1 plasmids were previously described [25, 39, 41]. After transfection for 48 h, the transfected 
cells were used for subsequent assays. 
 
Tissue Preparation 
For human samples, formalin-fixed (4%, 24 h), paraffin-embedded tissue from cortex and striatum 
were used. Sections (5-μm thick) were mounted on superfrost-plus tissue slides (Menzel-Gläser) and 
deparaffinized. Peroxidase activity was quenched with 0.3% H2O2 in methanol for 30 min, followed 
by antigen retrieval with 10 mM pH 6.0 citrate buffer heated by microwave for 15 min. 
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Mice euthanasia was performed using CO2. Brains were immediately removed and dissected on an 
ice-cold plate and left hemispheres, processed for histology, placed in 4% paraformaldehyde in 
Sorensen’s phosphate buffer overnight and then immersed in 30% sucrose in PBS for 72 h. Once 
cryoprotected, samples were included in optimum cutting temperature (OCT) compound (Tissue-
Tek, Sakura Finetek Europe, ref. 4583), frozen and stored at −80 °C before use. 30 µm sagiƩal 
sections were cut on a cryostat (Thermo Scientific), collected and stored free floating in glycol 
containing buffer (30% glycerol, 30% ethylene glycol in 0.02 M phosphate buffer) at −20 °C. 
 
Immunohistochemistry and Immunofluorescence 
For immunohistochemical staining, sections were first washed with PBS and immersed in 0.3% H2O2 
in PBS for 45 min to quench endogenous peroxidase activity. Sections were then immersed for 1 h 
in blocking solution (PBS containing 0.5% Fetal Bovine Serum, 0.3% Triton X-100 and 1% BSA) and 
incubated overnight at 4 °C with rabbit anti-ATF5 (1:1000, AVIVA, ARP30970) diluted in blocking 
solution. After washing, brain sections were incubated first with biotinylated goat anti-rabbit 
secondary antibody and then with avidin–biotin complex using the Elite Vectastain kit (Vector 
Laboratories, PK-6101-2). Chromogen reactions were performed with diaminobenzidine (SIGMA-
FAST DAB, Sigma, D4293) for 10 min. Mouse sections were mounted on glass slides and coverslipped 
with Mowiol (Calbiochem, Cat. 475904) while human sections where first dehydrated and then 
mounted with DePex (SERVA). Images were captured using an Olympus BX41 microscope with an 
Olympus camera DP-70 (Olympus Denmark A/S).  
For immunofluorescence, brain sections and N2a coverslips were pretreated with 0.1% Triton X-100 
for 30 min, 1 M glycine for 15 min and blocking solution (1% BSA, 0.3% FBS and 0.1% Triton X-100) 
for 1 h. Sections were then incubated overnight at 4 °C with rabbit anti-ATF5 (1:1000, AVIVA, 
ARP30970) and goat anti-huntingtin (1:200, N-18 Santa Cruz, sc-8767) in blocking solution.  The 
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following day, sections were washed in PBS and incubated with secondary antibodies for 1 h: anti-
goat Alexa 555 (1:500, ThermoFisher, A-21432) and anti-rabbit Alexa 488 (1:500, ThermoFisher, A-
21206). After washing, nuclei were counterstained with DAPI (1:5000, Calbiochem, 28718-90-3) for 
3 min. Finally, sections were mounted on glass slides, coverslipped with Mowiol (Calbiochem, 
475904) and maintained at 4 °C. N2a coverslips were co-incubated with rabbit anti-cleaved caspase 
3 (1:100, Cell Signaling, 9579) and goat anti-ATF5 (1:1000, Santa Cruz, sc-377168) for 1 h at room 
temperature. Coverslips were then washed with PBS and co-incubated with anti-goat Alexa 555 (A-
21432) and anti-rabbit Alexa 647 (A-31573) for 1 h. Nuclei were counterstained as with tissue 
sections. Coverslips were mounted in FluorSave (Calbiochem, Merck KGaA). Images were acquired 
with a laser confocal LSM710 system coupled to the invert Axioobserver microscope with a 63×, 1.4 
numerical aperture oil-immersion objective using the Zen2010B sp1 software (Carl Zeiss). Sequential 
optic sections (1 μm) were acquired in z stacks. Images were processed using ImageJ 1.45s. 
 
Western Blot 
Samples from human brain were stored at −80 °C and ground with a mortar in a frozen 
environment with liquid nitrogen to prevent thawing of the samples, resulting in tissue powder. 
Mouse brains were quickly dissected on an ice-cold plate and the different structures stored 
at −80 °C. Human and mouse protein extracts were prepared by homogenizing brain 
structures in ice-cold extraction buffer [20 mM HEPES pH 7.4, 100 mM NaCl, 20 mM NaF, 1% 
Triton X-100, 1 mM sodium orthovanadate, 1 μM okadaic acid, 5 mM sodium pyrophosphate, 30 
mM β-glycerophosphate, 5 mM EDTA, protease inhibitors (Complete, Roche, Cat. No 
11697498001)]. Homogenates were centrifuged at 15,000 rpm for 15 min at 4 °C. The resulting 
supernatant was collected, and protein content determined by Quick Start Bradford Protein Assay 
(Bio-Rad, 500-0203). 20 μg of total protein were electrophoresed on 10% SDS–polyacrylamide gel, 
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transferred to a nitrocellulose blotting membrane (Amersham Protran 0.45 μm, GE Healthcare Life 
Sciences, 10600002) and blocked in TBS-T (150 mM NaCl, 20 mM Tris–HCl, pH 7.5, 0.1% Tween 20) 
supplemented with 5% non-fat dry milk. Membranes were incubated overnight at 4 °C with either 
rabbit anti-ATF5 (1:1000, AVIVA, ARP30970), rabbit anti-MCL1 (1:1000, Santa Cruz, sc-819), mouse 
anti-TUBB3 (1:5000; Novus Biologicals, NB120-11314) or mouse anti-β-ACTIN (1:50,000, SIGMA, 
A2066) in TBS-T supplemented with 5% non-fat dry milk, washed with TBS-T and next incubated 
with HRP-conjugated anti-rabbit IgG (1:2000, DAKO, P0448) and developed using the ECL detection 
kit (PerkinElmer, NEL105001EA). 
 
Data analysis.  
Statistical analysis was performed with SPSS 21.0 (SPSS® Statistic IBM®). Data are represented as 
Mean ± SEM (standard error of the mean). The normality of the data was analyzed by Shapiro–Wilk 
or Kolmogorov–Smirnov tests. For two-group comparison, two-tailed t Student’s test was 
performed. For multiple comparisons, data were analyzed by one way-ANOVA test followed by an 
LSD or a Games–Howell post hoc test. A critical value for significance of p < 0.05 was used 
throughout the study. 
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Results 
 
ATF5 is sequestered into neuronal polyQ inclusions in HD mouse model and human tissue 
We first performed ATF5 immunohistochemistry (IHC) on brain sections from an HD mouse model 
and matching wild type mice. More precisely, we analyzed the widely used R6/1 transgenic mouse 
model of expanded CAG/polyQ disease that ubiquitously expresses N-terminal huntingtin (HTT) with 
115 CAG repeats [23]. Cortex and striatum were analyzed as these are the most affected brain 
regions in HD and the most salient feature was the bold accumulation of ATF5 immunoreactivity in 
neuronal nuclear inclusion bodies (IBs) in both brain regions of R6/1 but not in wild type mice (Fig. 
1a). Interestingly, this accumulation of ATF5 in IBs of R6/1 mice is an early event as it can be 
observed from an early-symptomatic age (3.5 months). We then performed ATF5 IHC on human HD 
and control tissue which for the first time demonstrated expression of ATF5 in human adult neurons 
(Fig. 1b) in line with our previous observations in mouse tissue [41]. Furthermore, ATF5 
immunostaining also confirmed accumulation of ATF5 into neuronal nuclear aggregates that 
resemble the characteristic polyQ IBs in HD brains (Fig. 1b). Apart from nuclear inclusions, HD 
patients also show inclusions in the soma and neurites and, interestingly, ATF5 can also be found in 
cytoplasmic inclusions in the soma, in neuritic inclusions, and in neuropil inclusions (Fig. 1c). 
To confirm that ATF5 is in fact being sequestered into the polyQ-containing neuronal nuclear IBs, 
we performed double immunofluorescence with antibodies against ATF5 and N-terminal mutant 
HTT (mHTT). As shown in Fig. 2, ATF5-positive nuclear inclusions colocalized with mHTT nuclear 
inclusions both in R6/1 mouse tissue (Fig. 2a) (Pearson correlation coefficient = 0.7) and in human 
HD tissue (Fig. 2b) (Pearson correlation coefficient = 0.78). 
 
 
11 
 
Decreased ATF5 levels in striatum and cortex of HD mouse model and human tissue 
We then performed Western blot analysis to test whether accumulation of ATF5 within mHTT IBs 
correlates with decreased levels of soluble monomeric ATF5. We decided to analyze R6/1 mice at 
the age of 3.5 months when they are pre- or early-symptomatic with very little striatal atrophy 
and neuronal loss [22] and we observed  a 40.5% reduction of ATF5 levels in the striatum respect 
to wild type (p = 0.0003) (Fig. 3a). In cortex of R6/1 mice, we also observed a significant although 
less pronounced decrease in the levels of ATF5 (18.9% decrease, p < 0.05) (Fig. 3a). In HD patient 
postmortem brains, we also observed decreased ATF5 levels both in cortex and 
caudate/putamen, with respect to samples from control subjects (Fig. 3b). In this case, the 
decrease was more pronounced and more significant in cortex (78.5% decrease, p = 0.0001) than 
in striatal nuclei (24.7% decrease, p = 0.006). Since HD patient postmortem striatum do show 
significant neuronal loss, we decided to normalize the levels of ATF5 to the level of the neuronal 
marker beta-III tubulin (TUBB3) [4]. When applying this correction for the effect of neuronal loss, 
the ATF5 decrease is still significant in cortex (66.2% decrease, p = 0.04) while only a tendency in 
striatum. This suggests that, at least in part, neuronal loss contributes to the decreased striatal 
ATF5 levels observed respect to total protein content. 
 
Decreased levels of the antiapoptotic ATF5 target MCL1 in striatum and cortex of HD mouse model 
and human tissue 
We then wondered whether decreased levels of ATF5 would correlate with decreased levels of its 
target MCL1 which has been proposed to play an important role in the antiapoptotic actions of ATF5 
[19, 37]. For this, we performed Western blot analysis of MCL1 on HD mouse model and human 
tissue samples. As expected, a marked decrease in MCL1 levels was observed in striatum (53.1% 
decrease, p < 0.0001) and in cortex (47.4% decrease, p = 0.016) of 3.5 month old R6/1 mice with 
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respect to age-matched wild type controls (Fig. 4a). Similar results of decreased MCL1 levels were 
also observed in striatum (77.7% decrease, p < 0.0001) and cortex (55% decrease, p = 0.002) of HD 
patients respect to control subjects (Fig. 4b). 
 
Deleterious effect of ATF5 deficiency in a C. elegans model of polyQ toxicity  
To gain insight into the potential deleterious effect of decreased ATF5 in an in vivo context of polyQ-
induced toxicity, we moved to the nematode model C. elegans. Specifically, we used a C. elegans 
strain that carries the transgene vzEx173 [Punc-54::Q40::yfp] resulting in the expression of a fusion 
protein Q40::YFP in worm muscle cells (Q40::yfp expression is controlled by the unc-54 myosin 
heavy chain gene promoter), causing an age-dependent aggregation phenotype whose readout is a 
progressive motility deficit [29]. Thus, we generated worms expressing the vzEx173 [Punc-
54::Q40::yfp] transgene in an atf-5(tm4397) null mutant background and found that lack of atf-5 
causes an increase in the number of Q40::YFP aggregates (Fig. 5a, b). Interestingly, while atf-5 
deficiency does not provoke any motility defect in otherwise wild type worms, we found a marked 
decrease in motility when the atf-5 mutation was introduced in the Q40::YFP expressing background 
(Fig. 5c). Similar results were obtained when using another independent transgene vzEx175 [Punc-
54::Q40::yfp] (data not shown). Together, these results indicate that decreased ATF5 levels 
exacerbate polyQ-toxicity in vivo. 
 
ATF5 protects from polyglutamine-induced apoptosis in a cell model of HD 
The decreased levels of ATF5 and of its antiapoptotic target MCL1 in the brain of the R6/1 HD mouse 
model and patients, together with the deleterious effect of atf-5 deficiency in polyQ-expressing C. 
elegans strains, suggest that increasing ATF5 levels might be beneficial through attenuation of 
polyQ-induced apoptosis. To test this, we performed experiments on N2a neuroblastoma cells. 
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First, we verified that transfection of an ATF5 expression vector increased both ATF5 and MCL1 
protein levels (Fig. 6a). Then, we verified that transfection of mHTT fused to CFP (PolyQ94), but not 
wild type N-terminal HTT fused to CFP (PolyQ16), resulted in IB formation (Fig. 6b, c) and in polyQ-
induced apoptosis as evidenced by cleaved caspase-3 immunofluorescence or by DAPI nuclear 
counterstaining (Fig. 6c, d). Co-transfection of ATF5 with PolyQ94 resulted in increased diffuse ATF5 
levels despite accumulation of ATF5 within polyQ inclusions (Fig. 6b). Besides, we observed that the 
incidence of apoptosis in PolyQ94 + ATF5 cells was much lower than in PolyQ94 cells and comparable 
to that in PolyQ16 cells (Fig. 6c, d), thus demonstrating that ATF5 overexpression is protective 
against polyQ-induced apoptosis. We also assayed the effect of the sole overexpression of MCL1 on 
polyQ94-induced apoptosis. As shown in Fig. 6e–g, MCL1 overexpression by itself also significantly 
reduced the rate of apoptosis induced by PolyQ94 to levels comparable to those in PolyQ16 cells. 
This confirms that the increased MCL1 levels induced by ATF5 overexpression contribute to the 
neuroprotective effect of ATF5. 
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Discussion 
Here we first report accumulation of ATF5 within the characteristic neuronal polyQ-containing IBs 
in the brain of HD mice starting at early-symptomatic ages and also in postmortem human HD brain 
tissue. This sequestration of ATF5 into IBs correlates with a decrease in the level of soluble ATF5 in 
both mouse and human HD tissue and with decreased levels of the antiapoptotic ATF5 target MCL1. 
Here we also analyze a nematode model of polyQ-induced toxicity which confirmed the deleterious 
effect of ATF5 deficiency. Finally, we show that ATF5 overexpression attenuates polyQ-induced 
apoptosis in a neuroblastoma cell model of HD. Together these results indicate that decreased levels 
of ATF5 in HD brain—probably secondary to its sequestration into polyQ IBs—render neurons more 
vulnerable to mutant huntingtin-induced apoptosis. 
 
We have previously shown that, contrary to the previous notion of adult neurons not expressing 
ATF5 [14], adult mice do show steady state levels of ATF5 expression in neurons [41]. Now, by 
showing ATF5 accumulation into neuronal IBs in human HD brain together with the diffuse ATF5 
immunostaining in neurons of control and HD brains, we here extend to humans the previous 
observation of ATF5 being expressed by adult neurons. 
 
There are different possible mechanisms by which ATF5 could accumulate into polyQ-containing IBs 
in brains of HD patients and mouse models. For instance, it is known that many transcription factors 
bind expanded polyQ stretches and are often found sequestered into IBs [32]. These include CREB-
binding protein (CBP), SP1, TBP, p53 [32] and many others such as the bZIP transcription factor 
C/EBPα [8]. Since bZIP containing transcription factors have the ability to form heterodimers [15], it 
is possible that ATF5 could reach the polyQ IBs through indirect interaction with any of the 
transcription factors previously reported to accumulate into polyQ IBs. Alternatively, it is known 
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that ATF5 has by itself propensity to aggregate in vitro [5, 6]. It is therefore possible that ATF5 could 
self-aggregate in vivo in pathophysiological conditions such as HD in which proteostasis and quality 
control mechanisms are compromised [7, 34, 44]. Such ATF5 microaggregates could then coalesce 
into mature IBs [21] such as those containing other polyQ-driven aggregates. 
 
We have mentioned that the decrease in soluble ATF5 might be secondary to its sequestration into 
IBs. An indicator in favor of this possibility is that the decrease in ATF5 protein levels in brain of HD 
mice and patients takes place without a matching decrease in its mRNA levels (data not shown). 
Therefore, the decrease in protein levels will most likely be secondary to decreased translation or 
to diminished half-life of the soluble protein, for instance because it gets aggregated. In fact, there 
are multiple examples of proteins whose sequestration into polyQ-IBs correlates with decreased 
soluble levels and loss of function [13, 26]. 
 
Regardless of the mechanism by which it takes place, we here provide evidence of decreased ATF5 
being deleterious, probably, because it contributes to a deficient execution of the UPR in HD in line 
with the previously reported deficient processing of ATF6 in HD patients and mouse models [11, 30]. 
Such deficient UPR execution will have proapoptotic effect as we show here that it is paralleled by 
a decrease in the levels of MCL1, a well-established target of ATF5 with antiapoptotic actions. 
Therefore, in line with the here shown neuroprotective effect of ATF5 overexpression in a cell model 
of HD, any pharmacological intervention able to increase ATF5 levels in HD might be of therapeutic 
value. In this regard, salubrinal, guanabenz and sephin1 are small drugs that prolong eIF2α 
phosphorylation by inhibiting PPP1R15A (GADD34) and therefore modulate the UPR [9, 42]. 
Accordingly, salubrinal increases ATF5 levels in primary neuronal cultures [41] and it has been shown 
to attenuate cell death induced by the ER stress inducer tunicamycin [41] and also by N-terminal 
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mutant HTT [36]. This suggests that salubrinal or any other of the PPP1R15A inhibitors might be 
beneficial in HD. However, there might also be unwanted effects as in vivo administration of 
salubrinal has been reported to increase toxicity in a mouse model of prion-induced 
neurodegeneration [28]. 
 
In summary, here we report that reduced levels of ATF5 
in brain of HD patients, probably due to its sequestration into the characteristic PolyQ containing 
neuronal IBs, correlates with decreased levels of the antiapoptotic protein MCL1, a transcriptional 
target of ATF5. We also provide evidence of decreased ATF5 being deleterious by rendering neurons 
more vulnerable to polyQ-induced apoptosis, thus suggesting that ATF5-increasing pharmacological 
interventions might open future therapeutic opportunities for HD. 
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Fig. Legends 
 
Fig. 1 
As in rodents, ATF5 is expressed by adult human neurons and it accumulates in the characteristic 
HD nuclear inclusions in both species. a. Immunohistochemistry with ATF5 antibody in cortex (Cx; 
top) and striatum (St; bottom) of 3.5 month-age R6/1 and wild-type (WT) mice. Black arrowheads 
in R6/1 panels (left) show ATF5 accumulation into inclusion bodies in Cx and St. b. 
Immunohistochemistry with ATF5 antibody in Cx (top) and St (bottom) postmortem tissue of HD 
patients and control subjects. Black arrowheads in HD panels (left) show ATF5 accumulation into 
inclusion bodies in Cx and St. c. ATF5 immunohistochemistry and nuclear counterstaining in Cx post-
mortem tissue of HD patients. Black arrowheads indicate that ATF5 can be found not only in nuclear 
inclusions (both panels) but also in cytoplasmic inclusions in the soma (left panel), in neuritic 
inclusions (right panel), and in neuropil inclusions (right panel). White arrow-heads point to nucleoli 
to show that they are not coincident with the nuclear inclusions 
 
Fig. 2:  
Fig. 2 ATF5-positive neuronal nuclear inclusions colocalize with the characteristic polyQ-containing 
inclusions in HD mice and human tissue. Double immunofluorescence with ATF5 (green) and HTT 
(EM48, red) antibodies in St of 3.5 month-age R6/1 mice (a) and in Cx of HD patients (b). White 
arrowheads show ATF5 positive intra-nuclear inclusion bodies. Dashed lines delimit the regions 
taken for magnification and colocalization analysis. Orthogonal images (right panels) show 
colocalization of ATF5 and mHTT immunofluorescence projected in YZ and XZ axis. Nuclei were 
counterstained with DAPI (blue) 
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Fig. 3:  
Decreased ATF5 levels in striatum and cortex of HD mouse model and human tissue. a. 
Representative western blots of ATF5 protein levels in Cx and St of 3.5 month-age R6/1 mice (n = 9) 
and WT mice (n = 9). b. Representative western blots of ATF5 protein levels in Cx and St of HD 
patients (n = 9) compared to their respective controls (n = 9). ATF5 is normalized by β-ACTIN in all 
samples and also by TUBB3 in human samples. Histograms show quantification of ATF5 protein 
abundance with respect to control (Student’s t test; *p < 0.05, **p < 0.01, ***p < 0.001). Data 
represent mean ± SEM 
 
Fig. 4:  
Decreased levels of the antiapoptotic protein MCL1 in striatum and cortex of HD mouse model and 
human tissue. a. Representative western blots of MCL1 protein levels in Cx and St of 3.5 month-age 
R6/1 mice (n = 7) and WT mice (n = 7). b. Representative western blots of MCL1 protein levels in Cx 
and St of HD patients (n = 7) compared to their respective controls (n = 7). Histograms show 
quantification of MCL1 protein abundance with respect to control (Student’s t test; *p < 0.05, **p < 
0.01, ***p < 0.001). Data represent mean ± SEM 
 
Fig. 5: 
Deleterious effect of ATF5 deficiency in a C. elegans model of polyQ toxicity. a. Brightfield and 
fluorescence images of wt, atf-5(tm4397), Q40::yfp and Q40::yfp; atf-5(tm4397) worms. b. 
Quantification  of  the  number  of  Q40::YFP  aggregates  in Q40::yfp and Q40::yfp; atf-5(tm4397) 
animals (n = 20; Student’s t test; *p < 0.05). c. Quantification of the number of body bends/min in 
wt, atf-5(tm4397), Q40::yfp and Q40::yfp; atf-5(tm4397) worms (n = 20). Analysis of variance 
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(ANOVA), followed by minimum significant difference or Games–Howell, *p < 0.05, ***p < 0.001. 
Data represent mean ± SEM 
 
Fig. 6:  
ATF5 protects against polyQ-induced apoptosis in a cell model of HD. a. Representative western blot 
of ATF5 and MCL1 protein levels upon pcDNA-MYC-mATF5 (ATF5) transfection of N2a 
neuroblastoma cells. The histogram shows the abundance of MCL1 protein in transfected cells with 
respect to the control (Mock) (n = 6; Student’s t test). b. Immunofluorescence analysis of ATF5 
pattern in N2a cells transfected with toxic PolyQ94-CFP only (PolyQ94) or in combination with ATF5 
(PolyQ94 and ATF5) shows accumulation of ATF5 within polyQ-containing inclusions (yellow arrow-
heads) in both paradigms and that ATF5 overexpression results also in increased diffuse ATF5 
staining in PolyQ94 and ATF5. c. Apoptosis induction analysis by immunofluorescence of cleaved 
caspase-3 (c-c3) and nuclear morphology (DAPI) in N2a cells transfected with either PolyQ16, 
PolyQ94 or PolyQ94 and ATF5. d. Quantification of apoptotic cell death in N2a cells transfected with 
either PolyQ16, PolyQ94 or PolyQ94 and ATF5 with respect to the total number of cells counted (n 
= 300). Analysis of variance (ANOVA), followed by minimum significant difference or Games–Howell. 
e. Western blot analysis of MCL1 protein levels upon p3XFlag-CMV10-Flag-mMcl-1 (MCL1) 
transfection of N2a cells. The histogram shows the abundance of MCL1 protein in transfected cells 
with respect to the control (Mock) (n = 2; Student’s t test). f. Apoptosis induction analysis by 
immunofluorescence of cleaved caspase-3 (c-c3) and nuclear morphology (DAPI) in N2a cells 
transfected with either PolyQ16, PolyQ94 or PolyQ94 and MCL1. g. Quantification of apoptotic cell 
death in N2a cells transfected with either PolyQ16, PolyQ94 or PolyQ94 and MCL1 with respect to 
the total number of cells counted (n = 700). Analysis of variance (ANOVA), followed by minimum 
significant difference or Games–Howell, *p < 0.05, ***p < 0.001. Data represent mean ± SEM 
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